| HOME >> MEDICINE >> TECHNOLOGY |
2,500,0002,500,000Purchase of short-term investments
(5,000,000)(2,000,000)Purchases of property, plant and equipment
(94,506)(61,334)Purchases of intangible assets
(11,300)-Proceeds from sale of property, plant and equipment
-2,000Net cash (used in) provided by investing activities
(2,605,806)440,666Cash flows from financing activities:Net proceeds from public offering of common stock
14,917,059-Net proceeds from warrant and option exercise
2,275,906-Net cash provided by financing activities
17,192,965-Effect of exchange rates on cash and cash equivalents
(28,674)34,771Net increase (decrease) in cash and cash equivalents
13,076,418(1,483,432)Cash and cash equivalents at beginning of period
2,311,2693,276,299Cash and cash equivalents at end of period
$15,387,687$1,792,867Supplemental disclosure of cash flow information:Cash paid during the period for interest
$-$6,145Cash received(paid) during the period for income taxes
248(105,877)Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the rec
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2010 PR Newswire. All rights reserved |